Victoria DiMarco

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.

1 publication 2014 – 2014
Amino Acid SequenceBacterial ProteinsAntitoxinsBacterial ToxinsCatalytic Domain

What does Victoria DiMarco research?

Dr. DiMarco studies non-typeable Haemophilus influenzae, a bacterium often involved in respiratory infections. She examines a specific bacterial protein known as VapC1, which plays a crucial role in enabling bacteria to survive in harsh conditions, including the presence of antibiotics. By analyzing how various mutations in VapC1 affect its structure and function, she uncovers details about how bacteria can enter a dormant state that makes them hard to kill. This research aims to better understand bacterial behavior during infections and to inform the development of more effective treatments.

Key findings

  • Dr. DiMarco discovered that specific regions of the VapC1 protein, particularly around its active site, are essential for its toxin function.
  • Her research showed that the partner protein VapB1 could still bind to and inhibit partially damaged versions of VapC1.
  • The findings indicate that understanding VapC1 mutations can provide insights into how bacteria hibernate and resist antibiotic treatment.

Frequently asked questions

Does Dr. DiMarco study antibiotic resistance?
Yes, her research focuses on how certain bacterial proteins, like VapC1, contribute to antibiotic resistance.
What is VapC1 and why is it important?
VapC1 is a bacterial protein that helps bacteria survive by making them toxic and allowing them to enter a dormant state, which is difficult to combat with antibiotics.
Can Dr. DiMarco's work help in developing new treatments?
Absolutely, her findings can lead to new strategies aimed at preventing bacteria from entering their resistant, dormant state.

Publications in plain English

Analysis of non-typeable Haemophilous influenzae VapC1 mutations reveals structural features required for toxicity and flexibility in the active site.

2014

PloS one

Hamilton B, Manzella A, Schmidt K, DiMarco V, Butler JS

Plain English
Researchers studied a bacterial survival protein called VapC1 by deliberately breaking it in different ways to understand which parts make it work as a toxin that helps bacteria enter a dormant, hard-to-kill state during infections. They found that specific regions of the protein, especially around its active site where it does its damage, are critical for its toxic function, and that a partner protein called VapB1 can still bind to and disable even partially broken versions of the toxin. These discoveries reveal how bacteria build the molecular machinery that lets them hibernate and survive antibiotic treatment, which could eventually help doctors design better ways to fight stubborn infections.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.